Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT.

Albuquerque K, Giangreco D, Morrison C, Siddiqui M, Sinacore J, Potkul R, Roeske J.

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1043-7. doi: 10.1016/j.ijrobp.2009.12.025. Epub 2010 May 12.

PMID:
20471182
2.

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.

Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1356-65. Epub 2006 Jun 6.

PMID:
16757127
3.

Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.

Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D'Souza D, Souhami L, Small W Jr, Gaur R, Jhingran A.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):83-90. doi: 10.1016/j.ijrobp.2013.01.017.

4.
5.

Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.

Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B.

Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1504-10. doi: 10.1016/j.ijrobp.2008.04.046.

PMID:
18640499
6.

Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.

Simpson DR, Song WY, Moiseenko V, Rose BS, Yashar CM, Mundt AJ, Mell LK.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e81-6. doi: 10.1016/j.ijrobp.2011.12.012.

PMID:
22516388
7.

Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Rose BS, Aydogan B, Liang Y, Yeginer M, Hasselle MD, Dandekar V, Bafana R, Yashar CM, Mundt AJ, Roeske JC, Mell LK.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):800-7. doi: 10.1016/j.ijrobp.2009.11.010. Epub 2010 Apr 17.

8.

Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.

Liang Y, Bydder M, Yashar CM, Rose BS, Cornell M, Hoh CK, Lawson JD, Einck J, Saenz C, Fanta P, Mundt AJ, Bydder GM, Mell LK.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):406-14. doi: 10.1016/j.ijrobp.2012.04.044. Epub 2012 Jun 9.

PMID:
22687195
10.

Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer.

Chen CC, Lin JC, Jan JS, Ho SC, Wang L.

Gynecol Oncol. 2011 Jul;122(1):9-13. doi: 10.1016/j.ygyno.2011.03.034. Epub 2011 Apr 22.

PMID:
21514629
11.

Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data.

Liang Y, Messer K, Rose BS, Lewis JH, Jiang SB, Yashar CM, Mundt AJ, Mell LK.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):912-9. doi: 10.1016/j.ijrobp.2009.11.062. Epub 2010 May 14.

12.

Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.

Erpolat OP, Alco G, Caglar HB, Igdem S, Saran A, Dagoglu N, Aslay I, Ozsaran Z, Demirci S, Keven E, Guney Y, Akmansu M, Kilic D, Bayman E, Etiz D, Mandel NM.

Eur J Gynaecol Oncol. 2014;35(1):62-6.

PMID:
24654465
13.

Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.

Chang Y, Yang ZY, Li GL, Li Q, Yang Q, Fan JQ, Zhao YC, Song YQ, Wu G.

Int J Gynecol Cancer. 2016 May;26(4):770-6. doi: 10.1097/IGC.0000000000000660.

PMID:
26844613
14.

Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients.

Chen MF, Tseng CJ, Tseng CC, Yu CY, Wu CT, Chen WC.

Cancer J. 2008 May-Jun;14(3):200-6. doi: 10.1097/PPO.0b013e318173a04b.

PMID:
18536561
15.

Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1431-7. Epub 2007 Nov 8.

PMID:
17996390
16.
17.

Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix.

Gerszten K, Colonello K, Heron DE, Lalonde RJ, Fitian ID, Comerci JT, Selvaraj RN, Varlotto JM.

Gynecol Oncol. 2006 Aug;102(2):182-8. Epub 2006 Mar 3.

PMID:
16516281
18.
19.

Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer.

Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, Kelley JL, Edwards RP.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):166-71. Epub 2007 Feb 22.

PMID:
17321070
20.

Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.

Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, Yang SN, Lin FJ.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1370-7. Epub 2006 Sep 18.

PMID:
16979836

Supplemental Content

Support Center